Skip to main content
SNDX
NASDAQ Life Sciences

CEO Michael Metzger Receives Substantial Equity Awards

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$20.8
Mkt Cap
$1.826B
52W Low
$8.58
52W High
$22.73
52W Position info
142% above low
Off High info
8.5% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

SNDX has more than doubled off its 52-week low of $8.58.

Summary

Syndax Pharmaceuticals CEO Michael Metzger was granted significant equity awards, including restricted stock units and stock options, totaling approximately $8.99 million.


Key Events · Ownership and Investor Activity · SNDX

  • CEO Granted Significant Equity Awards

    CEO Michael Metzger received restricted stock units and stock options valued at approximately $8.99 million, increasing his potential ownership in the company.

  • Routine Tax-Related Share Sale

    A sale of 7,412 shares totaling $152,835 occurred to cover tax withholding obligations from RSU vesting, a common practice for equity compensation.


Analysis · SNDX · Life Sciences

This Form 4 filing details a significant equity compensation package for CEO Michael Metzger, comprising restricted stock units (RSUs) and stock options. The awards, valued at approximately $8.99 million, represent a substantial increase in the CEO's potential ownership in the company, aligning his interests with long-term shareholder value. A smaller, routine sale of shares occurred to cover tax withholding obligations related to RSU vesting.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SNDX was trading at $20.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $8.58 to $22.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNDX - Latest Insights

SNDX
Nov 02, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.91
Real-time Price: $9.32 info
Change: -$3.59 (-28%) info
Market Cap: $843.565M info
SNDX
Nov 02, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.90
Real-time Price: $9.32 info
Change: -$3.58 (-28%) info
Market Cap: $843.565M info
SNDX
Aug 04, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.76
Real-time Price: $9.32 info
Change: -$8.44 (-48%) info
Market Cap: $843.565M info
SNDX
Aug 04, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.98
Real-time Price: $9.32 info
Change: -$8.66 (-48%) info
Market Cap: $843.565M info
SNDX
Jul 14, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.89
Real-time Price: $9.32 info
Change: -$13.57 (-59%) info
Market Cap: $843.565M info